Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-Operative mFOLFIRINOX in Localized Pancreatic Cancer
NCT02047474Phase 2Completed
- Sponsor
- Yale University
- Start
- Mar 2014
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil in pancreatic cancer (PC), sponsored by Yale University. Started Mar 2014; status: completed.
02
Drugs
oxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02047474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047474.